Stocks and Investing
Stocks and Investing
Wed, July 12, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, July 11, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, July 10, 2017
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Lewis Maintained (ABT) at Hold with Increased Target to $49 on, Jul 10th, 2017
David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Hold with Increased Target from $45 to $49 on, Jul 10th, 2017.
David has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Isaac Ro of "Goldman Sachs" Initiated at Hold and Held Target at $45 on, Tuesday, May 16th, 2017
- Joanne Wuensch of "BMO Capital" Downgraded from Buy to Hold on, Tuesday, March 14th, 2017
This is the rating of the analyst that currently disagrees with David
- Christopher Pasquale of "Guggenheim" Initiated at Strong Buy and Held Target at $58 on, Thursday, June 29th, 2017
Contributing Sources